Machine Bio is developing a proprietary protein synthesis platform that produces pure proteins from DNA templates in a single-step, four-hour process. This technology enables rapid and efficient protein production for applications in drug discovery, synthetic biology, and therapeutic manufacturing.
Funding
$200K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current protein synthesis methods often involve multi-step processes that are time-consuming and can result in low yields of pure protein. This inefficiency hinders research and development efforts across various fields, including drug discovery, synthetic biology, and therapeutic manufacturing.
Solution
Machine Bio offers a protein synthesis platform that streamlines the production of pure proteins directly from DNA templates. Their technology enables a single-step process completed in approximately four hours, significantly reducing the time and complexity associated with traditional protein synthesis methods. This rapid and efficient protein production accelerates research cycles and facilitates the development of new therapies and biotechnological applications. The platform's ease of use and high purity output make it a valuable tool for scientists and researchers across diverse disciplines.
Target Audience
The primary target audience includes researchers and scientists in drug discovery, synthetic biology, and related fields, as well as companies involved in therapeutic manufacturing and industrial enzyme optimization.
Features
- Single-step protein synthesis process completed in four hours
- Direct protein production from DNA templates
- High-purity protein output
- Easy-to-use platform
- Applicable to drug discovery, synthetic biology, industrial enzyme optimization, and therapeutic manufacturing